Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.

Blaszczak W, Barczak W, Wegner A, Golusinski W, Suchorska WM.

Med Oncol. 2017 Apr;34(4):60. doi: 10.1007/s12032-017-0918-1. Epub 2017 Mar 17. Review.

2.

MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells.

Todorova PK, Mukherjee B, Burma S.

Ann Transl Med. 2017 Feb;5(3):61. doi: 10.21037/atm.2017.01.67. No abstract available.

3.

MET overexpression and gene amplification in NSCLC: a clinical perspective.

Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F.

Lung Cancer (Auckl). 2013 Jun 18;4:15-25. doi: 10.2147/LCTT.S35168. eCollection 2013. Review.

4.

MET targeted therapy for lung cancer: clinical development and future directions.

Feng Y, Ma PC.

Lung Cancer (Auckl). 2012 Aug 9;3:53-67. doi: 10.2147/LCTT.S23423. eCollection 2012. Review.

5.

Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.

Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, Park HG, Han SI, Kang HS.

Mol Cancer. 2017 Jan 30;16(1):10. doi: 10.1186/s12943-016-0577-4. Review.

6.

AEG-1 knockdown in colon cancer cell lines inhibits radiation-enhanced migration and invasion in vitro and in a novel in vivo zebrafish model.

Gnosa S, Capodanno A, Murthy RV, Jensen LD, Sun XF.

Oncotarget. 2016 Dec 6;7(49):81634-81644. doi: 10.18632/oncotarget.13155.

7.

Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors.

Esfahani SA, Heidari P, Kim SA, Ogino S, Mahmood U.

Theranostics. 2016 Sep 9;6(12):2028-2038. eCollection 2016.

8.

Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer.

Stella GM, Gentile A, Baderacchi A, Meloni F, Milan M, Benvenuti S.

J Transl Med. 2016 Sep 2;14:256. doi: 10.1186/s12967-016-1008-4. Review.

9.

The Current and Future Treatment of Brain Metastases.

Hardesty DA, Nakaji P.

Front Surg. 2016 May 25;3:30. doi: 10.3389/fsurg.2016.00030. eCollection 2016. Review.

10.

Met and its ligand HGF are associated with clinical outcome in breast cancer.

Veenstra C, Pérez-Tenorio G, Stelling A, Karlsson E, Mirwani SM, Nordensköljd B, Fornander T, Stål O.

Oncotarget. 2016 Jun 14;7(24):37145-37159. doi: 10.18632/oncotarget.9268.

11.

Phenotypic Transition as a Survival Strategy of Glioma.

Ichikawa T, Otani Y, Kurozumi K, Date I.

Neurol Med Chir (Tokyo). 2016 Jul 15;56(7):387-95. doi: 10.2176/nmc.ra.2016-0077. Epub 2016 May 11.

12.

MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.

De Bacco F, D'Ambrosio A, Casanova E, Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL, Luraghi P, Reato G, Pellegatta S, Finocchiaro G, Perera T, Garibaldi E, Gabriele P, Comoglio PM, Boccaccio C.

EMBO Mol Med. 2016 May 2;8(5):550-68. doi: 10.15252/emmm.201505890. Print 2016 May.

13.

c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo.

Jia Y, Dai G, Wang J, Gao X, Zhao Z, Duan Z, Gu B, Yang W, Wu J, Ju Y, Wang M, Li Z.

Oncol Lett. 2016 Apr;11(4):2879-2885. Epub 2016 Mar 3.

14.

MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer.

Stella GM, Senetta R, Inghilleri S, Verdun di Cantogno L, Mantovani C, Piloni D, Scudeller L, Meloni F, Papotti M, Ricardi U, Cassoni P.

Neuro Oncol. 2016 Apr;18(4):598-9. doi: 10.1093/neuonc/nov325. Epub 2016 Feb 23. No abstract available.

15.

HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes.

Cui J, Xia T, Xie D, Gao Y, Jia Z, Wei D, Wang L, Huang S, Quan M, Xie K.

Oncogene. 2016 Sep 8;35(36):4708-18. doi: 10.1038/onc.2016.14. Epub 2016 Feb 15.

16.

Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor.

Cho O, Hwang HS, Lee BS, Oh YT, Kim CH, Chun M.

Radiat Oncol J. 2015 Dec;33(4):328-36. doi: 10.3857/roj.2015.33.4.328. Epub 2015 Dec 30.

17.

PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.

Yan LX, Liu YH, Xiang JW, Wu QN, Xu LB, Luo XL, Zhu XL, Liu C, Xu FP, Luo DL, Mei P, Xu J, Zhang KP, Chen J.

Int J Oncol. 2016 Feb;48(2):471-84. doi: 10.3892/ijo.2015.3287. Epub 2015 Dec 10.

18.

Cross talk of tyrosine kinases with the DNA damage signaling pathways.

Mahajan K, Mahajan NP.

Nucleic Acids Res. 2015 Dec 15;43(22):10588-601. doi: 10.1093/nar/gkv1166. Epub 2015 Nov 5. Review.

19.

Isothiocyanatostilbenes as novel c-Met inhibitors.

Gray AL, Coleman DT, Castore RF, Mohyeldin MM, El Sayed KA, Cardelli JA.

Oncotarget. 2015 Dec 1;6(38):41180-93. doi: 10.18632/oncotarget.5748.

20.

Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.

Kumar D, Kandl C, Hamilton CD, Shnayder Y, Tsue TT, Kakarala K, Ledgerwood L, Sun XS, Huang HJ, Girod D, Thomas SM.

JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1133-9. doi: 10.1001/jamaoto.2015.2381.

Supplemental Content

Support Center